Shree Ganesh Remedies Downgraded to 'Sell' by MarketsMOJO on November 11, 2024.

Shree Ganesh Remedies, a microcap pharmaceutical company, has recently been downgraded to a 'Sell' by MarketsMOJO on November 11, 2024. This decision was based on the company's flat results in September 2024 and its expensive valuation with a price to book value of 7.4. Despite its strong return of 54.80% in the past year, its profits have only increased by 26.9%, resulting in a PEG ratio of 1.9.
One of the reasons for the downgrade is the fact that domestic mutual funds hold only 0% of the company, indicating that they may not be comfortable with the current price or the business itself. However, the company does have a low debt to equity ratio and has shown healthy long-term growth with an annual net sales growth rate of 27.43%.

The technical trend for Shree Ganesh Remedies is currently sideways, indicating no clear price momentum. This trend has deteriorated from mildly bullish on November 11, 2024, and has resulted in a -3.45% return since then.

Despite its microcap size, Shree Ganesh Remedies has outperformed the market (BSE 500) with a return of 54.80% in the last year. However, with the recent downgrade and the company's flat results, investors may want to approach this stock with caution.